Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate (EryDex System) in Patients With Ataxia Telangiectasia Who Participated in the ATTeST-IEDAT-02-2015 Study
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ataxia telangiectasia
- Focus Adverse reactions; Registrational
- Acronyms OLE-IEDAT
- Sponsors EryDel; Quince Therapeutics
Most Recent Events
- 08 Oct 2024 Status changed from recruiting to discontinued. (terminated by sponsor)
- 04 May 2023 This trial has been completed in Norway (Date of the global end of the trial: 2 Sep 2022).
- 19 Apr 2023 This trial has been completed in belgium(Global end date 2/9/2022), according to European Clinical Trials Database record.